Virginia Hill

LG
h-index26
3papers
28citations
Novelty35%
AI Score31

3 Papers

LGSep 21, 2025
Training the next generation of physicians for artificial intelligence-assisted clinical neuroradiology: ASNR MICCAI Brain Tumor Segmentation (BraTS) 2025 Lighthouse Challenge education platform

Raisa Amiruddin, Nikolay Y. Yordanov, Nazanin Maleki et al.

High-quality reference standard image data creation by neuroradiology experts for automated clinical tools can be a powerful tool for neuroradiology & artificial intelligence education. We developed a multimodal educational approach for students and trainees during the MICCAI Brain Tumor Segmentation Lighthouse Challenge 2025, a landmark initiative to develop accurate brain tumor segmentation algorithms. Fifty-six medical students & radiology trainees volunteered to annotate brain tumor MR images for the BraTS challenges of 2023 & 2024, guided by faculty-led didactics on neuropathology MRI. Among the 56 annotators, 14 select volunteers were then paired with neuroradiology faculty for guided one-on-one annotation sessions for BraTS 2025. Lectures on neuroanatomy, pathology & AI, journal clubs & data scientist-led workshops were organized online. Annotators & audience members completed surveys on their perceived knowledge before & after annotations & lectures respectively. Fourteen coordinators, each paired with a neuroradiologist, completed the data annotation process, averaging 1322.9+/-760.7 hours per dataset per pair and 1200 segmentations in total. On a scale of 1-10, annotation coordinators reported significant increase in familiarity with image segmentation software pre- and post-annotation, moving from initial average of 6+/-2.9 to final average of 8.9+/-1.1, and significant increase in familiarity with brain tumor features pre- and post-annotation, moving from initial average of 6.2+/-2.4 to final average of 8.1+/-1.2. We demonstrate an innovative offering for providing neuroradiology & AI education through an image segmentation challenge to enhance understanding of algorithm development, reinforce the concept of data reference standard, and diversify opportunities for AI-driven image analysis among future physicians.

IVMar 12, 2021
Radiomic Deformation and Textural Heterogeneity (R-DepTH) Descriptor to characterize Tumor Field Effect: Application to Survival Prediction in Glioblastoma

Marwa Ismail, Prateek Prasanna, Kaustav Bera et al.

The concept of tumor field effect implies that cancer is a systemic disease with its impact way beyond the visible tumor confines. For instance, in Glioblastoma (GBM), an aggressive brain tumor, the increase in intracranial pressure due to tumor burden often leads to brain herniation and poor outcomes. Our work is based on the rationale that highly aggressive tumors tend to grow uncontrollably, leading to pronounced biomechanical tissue deformations in the normal parenchyma, which when combined with local morphological differences in the tumor confines on MRI scans, will comprehensively capture tumor field effect. Specifically, we present an integrated MRI-based descriptor, radiomic-Deformation and Textural Heterogeneity (r-DepTH). This descriptor comprises measurements of the subtle perturbations in tissue deformations throughout the surrounding normal parenchyma due to mass effect. This involves non-rigidly aligning the patients MRI scans to a healthy atlas via diffeomorphic registration. The resulting inverse mapping is used to obtain the deformation field magnitudes in the normal parenchyma. These measurements are then combined with a 3D texture descriptor, Co-occurrence of Local Anisotropic Gradient Orientations (COLLAGE), which captures the morphological heterogeneity within the tumor confines, on MRI scans. R-DepTH, on N = 207 GBM cases (training set (St) = 128, testing set (Sv) = 79), demonstrated improved prognosis of overall survival by categorizing patients into low- (prolonged survival) and high-risk (poor survival) groups (on St, p-value = 0.0000035, and on Sv, p-value = 0.0024). R-DepTH descriptor may serve as a comprehensive MRI-based prognostic marker of disease aggressiveness and survival in solid tumors.

QMJun 16, 2020
Can tumor location on pre-treatment MRI predict likelihood of pseudo-progression versus tumor recurrence in Glioblastoma? A feasibility study

Marwa Ismail, Virginia Hill, Volodymyr Statsevych et al.

A significant challenge in Glioblastoma (GBM) management is identifying pseudo-progression (PsP), a benign radiation-induced effect, from tumor recurrence, on routine imaging following conventional treatment. Previous studies have linked tumor lobar presence and laterality to GBM outcomes, suggesting that disease etiology and progression in GBM may be impacted by tumor location. Hence, in this feasibility study, we seek to investigate the following question: Can tumor location on treatment-naïve MRI provide early cues regarding likelihood of a patient developing pseudo-progression versus tumor recurrence? In this study, 74 pre-treatment Glioblastoma MRI scans with PsP (33) and tumor recurrence (41) were analyzed. First, enhancing lesion on Gd-T1w MRI and peri-lesional hyperintensities on T2w/FLAIR were segmented by experts and then registered to a brain atlas. Using patients from the two phenotypes, we construct two atlases by quantifying frequency of occurrence of enhancing lesion and peri-lesion hyperintensities, by averaging voxel intensities across the population. Analysis of differential involvement was then performed to compute voxel-wise significant differences (p-value<0.05) across the atlases. Statistically significant clusters were finally mapped to a structural atlas to provide anatomic localization of their location. Our results demonstrate that patients with tumor recurrence showed prominence of their initial tumor in the parietal lobe, while patients with PsP showed a multi-focal distribution of the initial tumor in the frontal and temporal lobes, insula, and putamen. These preliminary results suggest that lateralization of pre-treatment lesions towards certain anatomical areas of the brain may allow to provide early cues regarding assessing likelihood of occurrence of pseudo-progression from tumor recurrence on MRI scans.